AIT Therapeutics will present new research on the use of inhaled nitric oxide in the treatment of Mycobacterium abscessus lung infections at an upcoming conference, the company recently announced. Data from lab studies and a compassionate use study will be presented at the 3rd Annual World Bronchiectasis Conference July…
News
A potential therapy delivered through nanoparticles enables production of the normal, healthy form of the key CFTR protein in cystic fibrosis (CF), a new study suggests. The research, “Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis,” was published in the journal Molecular…
Cystic fibrosis (CF), once an exclusively pediatric disease, is clearly one no longer. Of the 32,000 or so Europeans registered with CF, nearly half are more than 18 years old, and babies born with the illness today can expect to live into their 50s and 60s. This means issues like…
Exercise clearly benefits kids with cystic fibrosis (CF), yet these children often lack the motivation to swim, run, box, play football or lift weights. A British healthcare conglomerate says it has found a way to get these kids moving — at no cost to them or their families. Nuffield…
Wales-based Neem Biotech recently received a Venture & Innovation Award from the U.K. Cystic Fibrosis Trust to develop new antimicrobial intervention strategies as part of its cystic fibrosis (CF) program. Neem researchers are working on a new approach to manage antimicrobial resistance through the prevention of…
Anxiety and depression among cystic fibrosis (CF) patients — and their parents — is far more common than most people realize, according to a panel of experts at the recent 41st European Cystic Fibrosis Conference (ECFS) in Belgrade, Serbia. The discussion featured eight mental health experts, and focused on…
The work of two faculty members at the University at Buffalo (UB), Jacob School of Medicine and Biomedical Sciences — Danielle M. Goetz, MD, and Carla A. Frederick, MD — were instrumental in the research that led to the approval of Symdeko (tezacaftor/ivacaftor and ivacaftor) for the treatment of…
Vertex Pharmaceuticals announced the opening of a 170,000-square-foot research facility in San Diego, representing a significant expansion of its research presence in the area. The San Diego site is one of Vertex’s three research hubs where the company’s approved, three disease-modifying cystic fibrosis (CF) medicines were discovered. More than 70…
The University of North Carolina (UNC) is among only a few institutions in the United States that offers patients with inflamed pancreas (pancreatitis) or pancreatic cystosis a surgical treatment option that allows a better outcome. It is relatively common for patients with cystic fibrosis (CF) to develop small cysts in…
SPX-101, designed to help clear mucus from the lungs of people with cystic fibrosis, has the potential to treat all CF patients — regardless of disease-causing mutations. The experimental peptide, which blocks the overactive sodium channels that line CF lung cells so more fluids are retained on airway surfaces to hydrate mucus,…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.